netFormulary South East London Joint Medicines Formulary NHS
Guy's and St Thomas' NHS Foundation Trust
Kings College Hospital NHS Foundation Trust
Lewisham and Greenwich NHS Trust
 
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Notes:

Please also refer to the Cancer Drugs Fund list

Where a formulary entry does not detail a medicine’s indications for use, the medicine can be assumed to be approved for all licensed indications.

Formulary approved "off-label" use is detailed separately.

 Details...
08.01.05  Expand sub section  Other antineoplastic drugs
 note  Use in accordance with local guidelines
08.01.05  Expand sub section  Amsacrine
08.01.05  Expand sub section  Bevacizumab
08.01.05  Expand sub section  Bexarotene
08.01.05  Expand sub section  Bortezomib to top
08.01.05  Expand sub section  Cetuximab
08.01.05  Expand sub section  Crisantaspase
08.01.05  Expand sub section  Dacarbazine and Temozolomide
Cytotoxic Drug Dacarbazine injection
View adult BNF View SPC online
Formulary
Red
 
   
Cytotoxic Drug Temozolomide caps (licensed use)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine

Approved as per NICE technology appraisal guidance

 
Link  NICE TA121: Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma
Link  NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)
   
Cytotoxic Drug Temozolomide caps (pancreatic neuroendocrine tumours - off-label)
View adult BNF View SPC online
Restricted Drug Restricted
Red

Approved off-label indication:

  • Unresectable or metastatic pancreatic neuroendocrine tumours (in combination with capecitabine). Follow local protocol for use. 
  •    
    Cytotoxic Drug Temozolomide caps (pituitary adenomas - off-label)
    View adult BNF View SPC online
    Restricted Drug Restricted
    Red

    Approved off-label indication:

    Treatment of pituitary adenomas refractory to surgery and radiotherapy

    Initiation restricted to Consultant Endocrinologists who are part of the Trust MDM, in accordance with a treatment protocol at KCH

     
       
    08.01.05  Expand sub section  Erlotinib
    08.01.05  Expand sub section  Hydroxycarbamide to top
    08.01.05  Expand sub section  Imatinab
    08.01.05  Expand sub section  Ipilimumab
    08.01.05  Expand sub section  Mitotane
    08.01.05  Expand sub section  Pentostatin
    08.01.05  Expand sub section  Platinum compounds to top
    08.01.05  Expand sub section  Procarbazine
    08.01.05  Expand sub section  Protein kinase inhibitors
    08.01.05  Expand sub section  Taxanes
    08.01.05  Expand sub section  Topoisomerase I inhibitors
    08.01.05  Expand sub section  Trabectedin to top
    08.01.05  Expand sub section  Trastuzumab
    08.01.05  Expand sub section  Tretinoin
     ....
    Key
    note Notes
    Section Title Section Title (top level)
    Section Title Section Title (sub level)
    First Choice Item First Choice item
    Non Formulary Item Non Formulary section
    Restricted Drug
    Restricted Drug
    Unlicensed Drug
    Unlicensed
    Track Changes
    Display tracking information
    click to search medicines.org.uk
    Link to adult BNF
    click to search medicines.org.uk
    Link to SPCs
    SMC
    Scottish Medicines Consortium
    Cytotoxic Drug
    Cytotoxic Drug
    CD
    Controlled Drug
    High Cost Medicine
    High Cost Medicine
    Cancer Drugs Fund
    Cancer Drugs Fund
    NHSE
    NHS England
    Homecare
    Homecare
    CCG
    CCG

    Traffic Light Status Information

    Status Description

    Red

    Specialist or hospital prescribing only. The responsibility for prescribing, monitoring, dose adjustment and review should remain with the specialist or hospital. In very exceptional circumstances a specialist may discuss individual patient need for a RED drug to be prescribed by a GP and the GP should consider informing the Medicines Management team before a decision is made to prescribe for individual patients.   

    Amber 1

    Treatment can be initiated in primary care after a recommendation from an appropriate specialist  

    Amber 2

    Specialist initiation followed by maintenance prescribing in primary care  

    Amber 3

    Specialist initiation with ongoing monitoring required. After dose stabilisation GPs can be requested to take over prescribing responsibilities using the approved APC shared care documentation  

    Green

    Specialist and non-specialist initiation  

    Grey

    Not recommended for prescribing  

    netFormulary